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Background: Upregulation of nuclear factor kappa B (NFκB) activity and neuroendocrine differentiation are two
mechanisms known to be involved in prostate cancer (PC) progression to castration resistance. We have observed
that major components of these pathways, including NFκB, proteasome, neutral endopeptidase (NEP) and
endothelin 1 (ET-1), exhibit an inverse and mirror image pattern in androgen-dependent (AD) and -independent
(AI) states in vitro.
Methods: We have now investigated for evidence of a direct mechanistic connection between these pathways
with the use of immunocytochemistry (ICC), western blot analysis, electrophoretic mobility shift assay (EMSA) and
proteasome activity assessment.
Results: Neuropeptide (NP) stimulation induced nuclear translocation of NFκB in a dose-dependent manner in AI
cells, also evident as reduced total inhibitor κB (IκB) levels and increased DNA binding in EMSA. These effects were
preceded by increased 20 S proteasome activity at lower doses and at earlier times and were at least partially
reversed under conditions of NP deprivation induced by specific NP receptor inhibitors, as well as NFκB, IκB kinase
(IKK) and proteasome inhibitors. AD cells showed no appreciable nuclear translocation upon NP stimulation, with
less intense DNA binding signal on EMSA.
Conclusions: Our results support evidence for a direct mechanistic connection between the NPs and NFκB/
proteasome signaling pathways, with a distinct NP-induced profile in the more aggressive AI cancer state.Introduction
The NFκB transcription factor controls many processes
that influence carcinogenesis and cancer progression.
Over-expression of NFκB and its transcribed genes are
involved in tumor growth, angiogenesis, metastasis,
and appear to be correlated with resistance to chemo-
therapy, advanced tumor stage, PSA recurrence and
pre-surgical PSA levels in PC [1-3]. Indeed, there is re-
cent evidence that IL-6 exposure (an NFκB target gene
product) induces neuroendocrine differentiation of PC
tumour sub-clones, conveying anti-apoptotic phenotype* Correspondence: cpapandreou@med.uth.gr
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reproduction in any medium, provided the orand resistance to chemotherapy [4,5]. Furthermore, ac-
tivation of NFκB was proved to be sufficient to main-
tain androgen-independent growth of prostate and PC
by up-regulating androgen receptor action [6].
The ubiquitin-proteasome system (UPS) is an indis-
pensable cellular regulatory machine with proteolytic
and non-proteolytic functions affecting many cancer-
related processes including cell cycle regulation, oxida-
tion damage control, apoptosis, cell trafficking, DNA
repair, transcription and chromatic re-modelling [7-10].
Ubiquitination regulates at least three steps in the NFκB
pathway: degradation of IκB, processing of NFκB precur-
sors, and activation of the IKK, the latter both
degradation-dependent and -independent [1,7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that include endogenous opioids Met- and Leu-
enkephalin, substance P, bradykinin, angiotensin 1 and 2,
ET-1 and bombesin (BBS)-like peptides. Acting as para-
crine hormones, they induce responses in many organ
systems [11-13]. In relevance to cancer, NPs act as po-
tent mitogens for many cancer types, including small-
cell lung cancer and PC [14,15]. NPs like ET-1 and BBS
have been shown to stimulate PC growth and new bone
formation in vitro [15-20], promote cell migration [21-
24] and show potent synergy with other growth factors
implicated in PC progression [22,25,26]. Advanced and
metastatic PC shows upregulated endothelin type A re-
ceptor (ETAR) and reduced endothelin type B receptor
(ETBR) expression, therefore sustaining unattenuated
ETAR-mediated ET-1 action [17,18], and higher plasma
ET-1 levels compared to hormone-naïve cancer [16].
This pattern of receptor expression also predicts recur-
rence of PC following radical prostatectomy [18]. Simi-
larly, advanced PC overexpresses gastrin-releasing
peptide (GRP) family receptors, via which BBS-like pep-
tides exert their action [27-30].
NEP is a cell membrane enzyme that hydrolyzes and
inactivates NPs [11-13]. During transition to androgen-
independence, NEP was shown to be downregulated or
silenced [31], frequently via promoter hypermethylation
[32]. Furthermore, it appears that androgen deprivation
therapy (ADT) leads to emergence of clones that have
downregulated NEP expression, as the latter is transcrip-
tionally activated by androgens [31,33,34]. This decrease
in NEP expression leaves unopposed the autocrine and
paracrine mitogenic action of NPs to act as an alterna-
tive growth pathway for PC cells in a low androgen en-
vironment [3,21,22,35].
The NFκB/UPS pathway and the NEP/NPs axis are
therefore two systems that have been previously shown
to be greatly involved in PC progression [1,3,16,31,36-
39], but not investigated for their precise interrelation
and dynamics. We have observed that with regard to the
steady state pattern between these two pathways in vitro,
AI cells have increased UPS/NFκB activation and a rich
NP milieu due to low NEP activity, while AD cells ex-
hibit an exact mirror image [40]. In this work we have
investigated the hypothesis that these pathways are dir-
ectly linked, and that this link has specific dynamics in
PC progression. Elucidation of such biological influences
could identify potential benefit from combined clinical
targeting of these pathways in castration-resistant,
advanced stage PC patients.
Materials and methods
Cell culture and reagents
LnCaP, PC-3 and HeLa cell lines were purchased from
the European Collection of Cell Cultures (ECACC,Health Protection Agency, Salisbury, UK) and all experi-
ments were performed within six months from purchase.
The lines were cultured in RPMI 1640 (Euroclone, UK)
supplemented with 10% heat-inactivated FBS (GIBCO,
UK), 5% L-glutamine (GIBCO, UK) and 1% penicillin-
streptomycin (Euroclone, UK) at 37°C in a humidified
5% CO2 atmosphere.
A series of incubations were performed, utilising ago-
nists and antagonists involved in the NEP/NPs and
NFκB/UPS pathways. ET-1 peptide and ETAR antagonist
(BQ-123) were purchased from Phoenix Pharmaceuticals,
Inc, Germany. BBS, BB2/GRP-preferring receptor antag-
onist (RC-3095), IKK inhibitor (wedelolactone), NFκB in-
hibitor (BAY 11–7082), and recombinant human tumor
necrosis factor α (rhTNFα) were from Sigma Aldrich,
UK. Proteasome inhibitor (Bortezomib, VELCADEW) was
purchased from Janssen-Cilag Pharmaceuticals, Greece.
Recombinant human NEP enzyme (rhNEP) was a kind
offer by Dr David Nanus, Weill Cornell Medical College,
New York, USA. Protein quantification was done with
the use of the Bradford quantification assay (Bio-Rad La-
boratories, Inc.) for the total cell lysates, and the BCA
Protein Kit (PIERCE Endogen, UK) for nuclear extracts.
Immunocytochemistry (ICC)
Cells were spread and cultured on glass slides. When at
80–90% confluency cells were fixed with MerckofixW
spray fixative (Merck KGaA, Darmstadt, Germany) and
conventional avidin-biotin ICC was performed. The Ven-
tana NexES Automated Slide Stainer and related Ventana
reagents were used. The samples were immersed in a cit-
rate buffer solution (pH 7.3) and heated for 15 min at
350 W. They were subsequently incubated with 3%
H2O2 for 4 min to quench the endogenous peroxidase
activity. A primary antibody against the p65 subunit of
NFκB was used in a 1:100 dilution. Diaminobenzidine
(DAB) was used as a chromogen for detection of the
antigens. Incubation with copper sulfate was performed
for enhancement of the colour reaction. The slides were
finally counterstained with haematoxylin and cover-
slipped for examination. A primary antibody against the
p65 subunit of NFκB (F-6, mouse monoclonal, Santa
Cruz Biotechnology, Inc.) was used.
Nuclear extracts
Nuclear extracts were prepared as described by Carter
et al. [41], with minor modifications as reported previ-
ously [42]. 106 cells were washed in cold PBS and col-
lected in 400 μl of ice-cold lysis buffer supplemented
with 10 μg/ml of protease inhibitors cocktail and then
incubated on ice for 20 min. Nonidet (NP-40) 10% was
added to lyse the cells which were vortexed and centri-
fuged for 20 sec at 4°C at 13,000 rpm. The pellet was
resuspended in 100 μl of extraction buffer for 20 min on
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minutes at 13,000 rpm and supernatant nuclear extracts
stored at −80°C until use.
Total cell lysates
Total protein cell lysates were prepared using a 0.5%
CHAPS buffer, which did not affect proteasomal enzym-
atic activity. Total lysates were also prepared using a sec-
ond buffer (containing 10 mM Tris–HCl, 50 mM EDTA,
150 mM NaCl, 1% Triton-X and 10% Glycerol) for west-
ern blotting purposes.
Western blot analysis
30 μg of total protein lysate or nuclear extract of each
sample were loaded on 4–12% Bis-Tris polyacrylamide
gels and underwent electrophoresis under reducing con-
ditions. Proteins were subsequently transferred on a
PVDF blotting membrane. Following blocking with 5%
non-fat milk, membranes with incubated with primary
antibodies at 4°C overnight. Primary antibodies against
the p65 subunit of NFκB (F-6, mouse monoclonal and
C-20, goat polyclonal Santa Cruz Biotechnology, Inc.),
IκBα (C-15, rabbit polyclonal, Santa Cruz Biotecnhology,
Inc.) and actin (clone AC-40, mouse monoclonal, Sigma
Aldrich, UK) were used. Secondary antibodies incuba-
tions were at a dilution of 1:2500 for 2 hours at room
temperature. Chemiluminescence detection (ECL detec-
tion reagent, Amersham Biosciences) with autoradiog-
raphy was used. Densitometric analysis of the bands in
blots was performed with the public domain software
for image analysis ‘ImageJ’ (National Institute of Health,
USA) [43]. All bands were measured in optical density
(OD) units and the mean densitometry values of differ-
ences in protein expression of three independent experi-
ments are presented as NFκB/actin or IκBα/actin ratios
respectively compared to baseline. (Western blot bands
are representative but not identical to the densitometry
values). Results are also presented in graphical form as a
percentage of the mean baseline NFκB/actin or IκBα/
actin ratios respectively.
Electrophoretic mobility shift assay
As NFκB consensus oligonuclotide we used the PRDII
element [44] of human IFN-beta enhancer (5′-TGG
CCAACATGGTGAAACCCCGTTTCTACT-3′) (IMBB,
Microchemistry Laboratory), labelled with [γ-32P] ATP
using T4 polynucleotide kinase. The probe was purified
through G50 columns (Amersham Biosciences) and then
EMSA was performed. Briefly, 3 μg of nuclear extracts
were incubated at room temperature for 20 min with
100 ng of labelled double-stranded oligonucleotide in
the presence of 20 ng of PolydI-dC (PIERCE Endogen,
UK) and 20 μg of BSA. Nuclear extracts from HeLa cells
(ATCC, UK) 6 hours post-infection with the Sendaiparamyxovirus (Cantell strain) and following incubation
with TNFα for 1 hour were used as positive controls.
For the supershift assay, nuclear extracts were incubated
with 1 μg of anti-p65 rabbit polyclonal antibody (Santa
Cruz Biotechnology, Inc.) for 30 min at 4°C, before the
addition of the probe. In every case, the protein-DNA
complexes were separated on a 7% non-denaturing poly-
acrylamide gel and bands were visualized using a Taeffun
Phospor-Imager/Scanner with the ImageQuant™ TL ana-
lysis software (Amersham Biosciences).
20S proteasome activity assay
Chymotryptic activity of the 20S proteasome in total cell
lysates was measured with a commercially available assay
based on the detection of fluorophore 7-Amino-4
-methylcoumarin (AMC) (Chemicon International,
USA), and was confirmed with the use of an AMC-
based in-house protocol assay. All experiments were
performed in quadruplicate and measured using a Wal-
lac Victor™ multilabel counter with 380 nm excitation
and 490 nm emission wavelengths. Baseline enzyme ac-
tivity was expressed as RFU/μg of total protein. Values
were compared against a fluorogenic substrate (LLVY-
AMC) standard curve and a 20 S proteasome control ac-
tivity curve. Changes in proteasomal activity were
expressed as percentage increase or decrease from base-
line activity of each line.
Statistical analysis
All data are expressed as the mean ± SEM of 3 or more
experiments, as indicated. The Graph Pad Instat Statis-
tical package for Windows was used. The one-way ana-
lysis of variance (ANOVA) with the Bonferroni post-test
was used for the comparison of data, and the statistical
significance limit was set at p< 0.05.
Results
NPs induce IκB-dependent activation of NFκB
We have previously shown that both ET-1 and BBS
stimulation at a dose of 100 nM for 60 min resulted in
increased nuclear NFκB amount in PC-3 but not in
LnCaP cells [45]. In this study, incubation of PC-3 cells
with different concentrations of ET-1 showed no appre-
ciable effect on NFκB localization at low concentrations
(1nM or 50nM). However, higher ET-1 concentration
(100nM) resulted in nuclear translocation of NFκB in
the great majority of cells. This effect was time-
dependent, evident at the 30-minute incubation and
gradually intensifying at the 45-and 60-minute incuba-
tion (Figure 1A).
Nuclear translocation in PC-3 cells was also achieved
with the use of BBS. As BBS was already used by others
[23] to successfully achieve nuclear translocation in PC-
3 cells at a specific incubation protocol (100nM for
Figure 1 NP effect on NFκB subcellular localisation. NFκB expression by ICC. (A) PC-3 cells, from left to right: baseline; ET-1 1nM, 50 nM and
100 nM, all incubations x 45 min; BQ-123 (1 μM x 30 min) and ET-1 (100nM x 45 min). (B) PC-3 cells, from left to right: baseline; BBS 100 nM,
incubations for 30 min, 45 min and 1 h; RC-3095 (10nM x 1 h) and BBS (100nM x 1 h).
Patrikidou et al. Cancer Cell International 2012, 12:31 Page 4 of 14
http://www.cancerci.com/content/12/1/3130 min), we designed a time-series (30, 45, 60, 120 min-
utes) for the same BBS concentration (100nM). Similar
to endothelin, BBS induced a time-dependent nuclear
translocation of NFκB, which started at 30 minutes,
intensified at 45 minutes and peaked at 1 hour
(Figure 1B).
Western blot analysis of nuclear extracts concurred
with the ICC results (Figure 1A, B), showing higher nu-
clear NFκB amount following NP stimulation in PC-3
cells (Figure 2A, B).
In order to demonstrate whether the observed nuclear
translocation of NFκB corresponded to actual transcrip-
tional activation effect, we performed EMSA analysis.
NP stimulation resulted in increased intensity of NFκB
binding signal in a time-dependent manner (Figure 3B,
C) similar to the one observed at ICC (Figure 1B). Peak
signal intensity was comparable to signal intensity of
PC-3 cells treated with TNFα, a well-known activator of
NFκB, as well as the signal intensity exhibited by HeLa
cells following TNFα incubation or viral infection as
above (Figure 3A, B).
NP incubation of PC-3 cells also resulted in a time-
dependent change in total IκBα status. IκBα levels were
already decreased at the 30-minute incubation, and con-
tinued dropping at longer incubations (up to 60 min-
utes) (Figure 4A, B, C, D).
NP stimulation using the same time and concentration
protocols had a relatively small effect on NFκB
localization in LnCaP cells, which remained cytoplasmic
(Figure 5A), and resulted in minimal increase in nuclearNFκB amount (Figure 5B). Being a more sensitive tech-
nique, EMSA analysis showed enhanced NFκB binding
signal in LnCaP cells after NP incubations, but to a
lesser degree compared to PC-3 cells (Figure 3A, C).
NP incubation resulted in no discernible decrease in
total IκBα amount in LnCaP cells at any incubation time
(Figure 5C) while there was a profound decrease in PC-
3 cells (Figure 4A, B, C, D). It is also obvious that the
NFκB/IκBα ratio is much higher than 1.0 in PC-3 while
is exactly the opposite in LnCaP where the ratio is lower
than 1.0.
NP-induced NFκB activation is blocked by UPS/NFκB
inhibitors
The UPS/NFκB inhibitors also blocked BBS– and ET-
1–induced nuclear translocation of NFκB in PC-3 cells.
Specifically, pre-incubation with proteasomal and IKK
inhibitors (bortezomib and wedelolactone respectively)
effectively prevented translocation, as did pre-incubation
with the NFκB inhibitor (BAY 11–7082). The latter also
had a visible effect on cell morphology (scattered, round,
apoptotic looking) as observed in previous incubations
(Figure 6A, B).
UPS/NFκB inhibitors also blocked the expected NP-
induced increase in nuclear NFκB amount, concurring
with the above (Figure 2A, B). Similarly, EMSA analysis
showed prevention or attenuation of NP-induced NFκB
binding with pre-incubations with the UPS/NFκB inhibi-
tors for both NPs (Figure 3A, B). Finally, pre-incubations
with proteasome (Figure 4B, D), IKK and NFκB
Figure 2 NP effect on nuclear NFκB amount. Nuclear extracts blots. (A) PC-3 cells, from left to right: baseline; ET-1 incubations (100 nM) x
30 min, 45 min and 60 min; BQ-123 (1 μM x 30 min) and ET-1 (100 nM x 60 min); pre-incubation with bortezomib (1 μM x 30 min) followed by
co-stimulation with ET-1 (100 nM) x 30 min, 45 min and 60 min; pre-incubations with BAY 11–7082 (20 μM x 16 h) and wedelolactone (50 μM x
90 min) followed by ET-1 incubations (100 nM x 1 h). (B) PC-3 cells, from left to right: baseline; BBS incubations (100 nM) x 30 min, 45 min and
60 min; RC-3095 (10 nM x 1 h) and BBS (100 nM x 1 h); pre-incubation with bortezomib (1 μM x 30 min) followed by co-stimulation with BBS
(100 nM) x 30 min, 45 min and 60 min; pre-incubations with BAY 11–7082 (20 μM x 16 h) and wedelolactone (50 μM x 90 min) followed by BBS
incubations (100 nM x 1 h). (C, D) Summary histograms of mean relative band densities for (A) and (B) normalized to actin expressed as a
percentage of baseline (*p< 0.05 versus baseline, #p< 0.05 between conditions as indicated by horizontal lines).
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Figure 3 NP effect on NFκB-DNA binding. EMSA. (A) From left to right: PC-3 cells, baseline; PC-3 cells, ET-1 incubation (100 nM x 45 min); PC-3
cells, pre-incubations with BQ-123 (1 μM x 30 min), bortezomib (1 μM x 60 min), wedelolactone (50 μM x 90 min) and BAY 11–7082 (20 μM x
16 h) followed by ET-1 incubation (100 nM x 45 min); LnCaP cells, baseline; LnCaP cells, ET-1 incubation (100 nM x 45 min); HeLa cells, infection
with Sentai paramyxovirus (Cantell strain) for 6 h. (B) From left to right: PC-3 cells, BBS incubations (100 nM) x 30 min, 45 min and 60 min;
pre-incubation with RC-3095 (10 nM x 1 h), wedelolactone (50 μM x 90 min), BAY 11–7082 (20 μM x 16 h) and bortezomib (1 μM x 60 min)
followed by BBS incubations (100 nM x 1 h); HeLa cells, rhTNF-α incubation (10 μM x 1 h). (C) From left to right: PC-3 cells, baseline; ET-1
incubations (100 nM) x 45 min and 60 min; BBS incubations (100 nM) x 45 min and 60 min. LnCaP cells, baseline; ET-1 incubations (100 nM)
x 45 min and 60 min; BBS incubations (100 nM) x 45 min and 60 min.
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IκBα amount documented with NP incubations alone.
As expected, pre-incubation with UPS/NFκB inhibitors
followed by NP stimulation had no effect on LnCaP cells
with regard to NFκB activation (Figure 6C, D).NP-induced NFκB activation is blocked by NP receptor
antagonists and NEP
The above noted nuclear translocation that ET-1 induced
in PC-3 cells was completely prevented with pre-
incubation with a selective antagonist of ETAR (Figure 1A).
Translocation was partially prevented by pre-incubation
with the BB2 receptor inhibitor (Figure 1B). When PC-3
cells were pre-incubated with rhNEP, subsequent incuba-
tion with either NP failed to result in visible nuclear trans-
location (Figure 7A). Pre-incubations with NP receptor
antagonists and rhNEP also blocked the increase in nuclearNFκB amount induced by NP incubations alone.
(Figure 2A, B, 7B).
In the same context, the NP-induced increase in
NFκB binding described above was partially prevented
by pre-incubation with the ETAR antagonist or BB2
receptor inhibitor (Figure 3A, B). Similarly, pre-
incubation with rhNEP resulted in significant attenu-
ation of the previously noted increase in NFκB binding
signal (Figure 7C).
Finally, pre-incubation with ETA and BB2 receptor inhi-
bitors and rhNEP all prevented the NP-induced reduction
in total cellular IκBα amount (Figure 4A, C, 7D).Upregulation of 20 S proteasome activity is an early
effect of NP stimulation
We have previously revealed a unimodal pattern of
proteasome activity upregulation in a concentration-
Figure 4 (See legend on next page.)
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Figure 4 NP effect on cellular IκBα amount. Total cell lysate blots. (A) PC-3 cells, from left to right: baseline; ET-1 incubations (100 nM) x
30 min, 45 min and 60 min; pre-incubations with BQ-123 (1 μM x 30 min), wedelolactone (50 μM x 90 min) and BAY 11–7082 (20 μM x 16 h)
followed by ET-1 incubation (100 nM x 45 min). (B) PC-3 cells, from left to right: baseline; pre-incubation with bortezomib (1 μM x 30 min)
followed by co-stimulation with ET-1 (100 nM) x 45 min and 60 min; ET-1 incubations (100 nM) x 30 min, 45 min and 60 min. (Different parts of
the same gel). (C) PC-3 cells, from left to right: baseline; BBS incubations (100 nM) x 30 min, 45 min and 60 min; pre-incubations with RC-3095
(10 nM x 1 h), wedelolactone (50 μM x 90 min) and BAY 11–7082 (20 μM x 16 h) followed by BBS incubation (100 nM x 45 min); pre-incubations
with RC-3095 (10 nM x 1 h), wedelolactone (50 μM x 90 min) and BAY 11–7082 (20 μM x 16 h) followed by BBS incubation (100 nM x 45 min).
(D) PC-3 cells, from left to right: baseline; pre-incubation with bortezomib (1 μM x 30 min) followed by co-stimulation with BBS (100 nM) x
45 min and 60 min; BBS incubations (100 nM) x 30 min, 45 min and 60 min. (Different parts of the same gel). (E-H) Summary histograms of mean
relative band densities for (A-D) normalized to actin expressed as a percentage of baseline (*p< 0.05 versus baseline, #p< 0.05 between
conditions as indicated by horizontal lines).
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[45].
Here, we have further performed time-series of NP-
stimulation experiments of the incubations that exhib-
ited peak proteasomal activities (40 nM for BBS and 80Figure 5 NP effect on NFκB subcellular localisation and cellular NFκB
expression by total cell lysate blots. (A) From left to right: LnCaP cells, base
30 min) and ET-1 (100 nM x 45 min); LnCaP cells, BBS (100 nM x 1 h); LnCa
to right: PC-3 cells, baseline; LnCaP cells, baseline; LnCaP cells, ET-1 incubat
x 45 min and 60 min. (C) From left to right: PC-3 cells, baseline; LnCaP cells
BBS incubations (100 nM) x 30 min, 45 min and 60 min.nM for ET-1) as well as of the standard concentration
used for the rest of the experiments (100 nM) in PC-3
cells. The ET-1 incubations showed peak activities at 45
minutes (Figure 8A), while the BBS incubations peaked
at 30 minutes (Figure 8B)., IκBα amount. NFκB expression by ICC and nuclear extract blots. IκBα
line; LnCaP cells, ET-1 (100 nM x 45 min); LnCaP cells, BQ-123 (1 μM x
P cells, RC-3095 (10 nM x 1 h) and BBS (100 nM x 45 min). (B) From left
ions (100 nM) x 45 min and 60 min; BBS incubations (100 nM)
, baseline; ET-1 incubations (100 nM) x 30 min, 45 min and 60 min;
Figure 6 UPS/NFκB pathway inhibitors prevent NP-induced nuclear translocation of NFκB. NFκB expression by ICC. (A) PC-3 cells, from
left to right: incubation with ET-1 (100 nM x 45 min) after pre-incubations with bortezomib (1 μM x 60 min), wedelolactone (50 μM x 90 min),
and BAY 11–7082 (20 μM x 16 h). (B) PC-3 cells, from left to right: incubation with BBS (100 nM x 1 h) after pre-incubations with bortezomib
(1 μM x 60 min), wedelolactone (50 μM x 90 min), and BAY 11–7082 (20 μM x 16 h). (C) LnCaP cells, from left to right: incubation with ET-1
(100 nM x 45 min) after pre-incubations with bortezomib (1 μM x 60 min), wedelolactone (50 μM x 90 min), and BAY 11–7082 (20 μM x 16 h).
(D) LnCaP cells, from left to right: incubation with BBS (100 nM x 1 h) after pre-incubations with bortezomib (1 μM x 60 min), wedelolactone
(50 μM x 90 min), and BAY 11–7082 (20 μM x 16 h).
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NP-inducible NFκB/UPS activation
We have observed that at baseline level there is an in-
verse expression pattern between the NEP/NPs and
NFκB/UPS pathways in AD and AI states in vitro [40].
We have also shown that NPs may act as inducers of
NFκB activation in PC-3 cells [45]. In the current work
we have further investigated whether this mirror pheno-
type of the two pathways at steady state also translates
to a dynamic relationship following dose- and time-
dependent stimulation and blocking of the NEP/NPs
pathway.
Our evidence shows that increasing concentrations of
ET-1 and BBS stimulate translocation of NFκB to the cell
nucleus in PC-3 cells (lacking NEP), with resultant acti-
vation of NFκB as a transcription factor, evident by
increased binding on DNA. Our results concur with
these of Levine et al. [23]. They showed that in PC-3 cells
BBS induced a time-dependent increase in DNA binding
of NFκB peaking at 1 hour which returned to near base-
line levels after that. Our results supplemented the above
by showing that BBS-induced nuclear translocation is
also time-dependent and peaks at the same time as thereported increase in NFκB binding (1 hour), the latter
also confirmed in our EMSA results. Furthermore, we
have shown that ET-1 has the exact same effect on NFκB
activation, evident both at ICC and EMSA analysis.
Our results strongly support that this effect on NFκB
activation is due to the NPs themselves and not a chance
association. No perceivable nuclear translocation oc-
curred at the same incubations in NEP-expressing
LnCaP cells with either ET-1 or BBS. EMSA analysis,
being a more sensitive technique did indeed detect a
level of NFκB binding activity in these cells, but this was
significantly lower compared to PC-3 cells. Similarly,
rhNEP incubation successfully prevented nuclear trans-
location and activation in PC-3 cells.
Further evidence was provided by the fact that this upre-
gulation in NFκB nuclear activity was prevented by the use
of the respective receptor inhibitors, and this was shown
both via ICC and EMSA. This indicates that this NP-
induced effect is receptor-mediated. ETAR blockade was
predictably able to completely prevent nuclear transloca-
tion, as it is established that the main receptor responsible
for mediating the mitogenic effects of ET-1 in PC cells is
indeed the ETA receptor. BB2 receptor blockade was
Figure 7 (See legend on next page.)
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Figure 7 rhNEP prevents NP-induced NFκB activation. (A) NFκB expression by ICC. PC-3 cells, from left to right: baseline, rhNEP (50 μg/ml x
16 h) and ET-1 (100 nM x 45 min); rhNEP (50 μg/ml x 16 h) and BBS (100 nM x 1 h). (B) Nuclear NFκB blot. PC-3 cells, from left to right: baseline;
rhNEP (50 μg/ml x 16 h) followed by ET-1 incubations (100 nM) x 45 min and 60 min; rhNEP (50 μg/ml x 16 h) followed by BBS incubations (100
nM) x 45 min and 60 min. (C) EMSA. PC-3 cells, from left to right: baseline; rhNEP (50 μg/ml x 16 h) followed by ET-1 incubations (100 nM) x
45 min and 60 min; rhNEP (50 μg/ml x 16 h) followed by BBS incubations (100 nM) x 45 min and 60 min. (D) Total cellular IκBα blot. PC-3 cells,
from left to right: baseline; rhNEP (50 μg/ml x 16 h) followed by BBS incubations (100 nM) x 45 min and 60 min; rhNEP (50 μg/ml x 16 h)
followed by ET-1 incubations (100 nM) x 45 min and 60 min; BBS incubations (100 nM) x 45 min and 60 min; ET-1 incubations (100 nM) x 45 min
and 60 min. (E, F) Summary histograms of mean relative band densities for (B) and (D) normalized to actin expressed as a percentage of baseline
(*p< 0.05 versus baseline, #p< 0.05 between conditions as indicated by horizontal lines).
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http://www.cancerci.com/content/12/1/31selected for our experiments based on the fact that prostate
carcinomas and PC-3 cells in specific are known to abun-
dantly express GRP-R [23,27,30] and that the mitogenic/
proliferative effects of BBS in prostate and other types of
cancer are predominantly mediated via BB2 receptor
[28,46]. However, BBS acts on two other receptors, neuro-
medin B receptor (NMB-R) and BBS receptor subtype 3
(BRS-3), shown to be expressed in 14% and 9% of prostate
carcinomas respectively [30]. Levine et al. assumed that
BBS-induced NFκB activation is due to activation of GRP-
R based on the ability of BB2 receptor antagonist to block
the BBS-induced increase in intracellular Ca++ [23].Figure 8 NP time-dependent effect on 20 S proteasomal activity (RFU
series of ET-1 incubations (80 nM) x 30 min, 45 min and 60 min; time serie
left to right: PC-3 cells, baseline; time series of BBS incubations (40 nM) x 3
30 min, 45 min and 60 min. Data represent the mean (± SEM) of three ind
percent of the initial value of proteasome activity (*p< 0.05 versus baselineHowever, our previously published concentration-series
results [45] suggest that the actual NFκB translocation and
preceding proteasomal activation is mainly but not com-
pletely due to activation of this receptor. Whether blocking
of the other two receptors as well would completely pre-
vent nuclear translocation of NFκB remains to be
elucidated.
We did not perform a separate analysis of the effect of
ET-1 and BBS receptor inhibitors on NFκB at baseline
(without NP stimulation). Firstly, a constitutive activation
of NFκB has been consistently reported in androgen-
independent PC-3 cells, at least partially mediated/μg) in PC-3 cells. (A) From left to right: PC-3 cells, baseline; time
s of ET-1 incubations (100nM) x 30 min, 45 min and 60 min. (B) From
0 min, 45 min and 60 min; time series of BBS incubations (100nM) x
ependent experiments performed in triplicate and are expressed as
, #p< 0.05 between conditions as indicated by horizontal lines).
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http://www.cancerci.com/content/12/1/31through epidermal growth factor receptors (EGFR) tyro-
sine kinases [47], the extracellular signal regulated
kinase-1/2 (ERK) [48], NF-κB-inducing kinase (NIK), and
IKK activation [38,49]. Therefore, it might seem unlikely
to detect a significant effect of NP receptor inhibitors on
protein levels and intracellular localization of NFκB at
baseline conditions, as NFκB is regulated by multiple sig-
naling pathways which do not necessarily involve up-
stream NP receptor binding. On the other hand, the use
of a specific NP receptor inhibitor in the NEP-expressing
LnCaP cells might not offer a significant additional
blockage of the mitogenic effects of NPs, including NFκB
activation, given that cleavage of NPs by NEP effectively
prevents NP receptor binding. In a previous study using
BQ-123 at a 10-fold higher dose compared to ours, no ef-
fect was observed on baseline secreted levels of IL-6,
which is a known NFκB-target gene [50]. In another
work, prolonged exposure (72 h) to high doses (25 μM)
of another endothelin receptor inhibitor (ABT-627) was
needed to produce a discernible effect on NFκB activity
[51]. Based on the results of our study examining the sti-
mulated activation of NFκB by ET-1 and BBS, it may be
suggested that this is at least partially a receptor-
mediated effect as it was reversed by their specific
inhibitors.
This effect is associated with increase in proteasomal
activity with resultant decrease in IκBα, suggesting that
the NP-induced nuclear translocation is IκB-dependent,
also prevented by use of NFκB/UPS inhibitors, NP re-
ceptor inhibitors and NEP. This suggests that the NP-
stimulated NFκB is indeed activated via the canonical
pathway.
NP-induced early proteasomal upregulation model
Our results specifically indicate that NPs are able to
upregulate 20 S proteasomal activity at lower concentra-
tions [45] and at shorter incubations than these neces-
sary to achieve NFκB activation. It can therefore be
deduced that the increase in proteasomal activity occurs
early during NP stimulation and precedes the NFκB nu-
clear translocation. So it might be that NPs induce pro-
teasomal activity, and when this reaches a critical level it
results in NFκB activation via decrease of total IκBα
status.
The NP-associated upregulation of proteasomal activ-
ity could also explain our finding that ETAR antagonist,
blocking the action of not only the exogenous but even
autocrine- and paracrine-acting ET-1 in PC-3 cells,
results in a 50% reduction of baseline proteasomal activ-
ity even if it is followed by ET-1 stimulation [45]. The
fact that BB2 receptor antagonist pre-incubation could
not reduce proteasomal activity to lower than baseline
[45] could be attributed to the fact that BBS might exert
its effect via other receptors as well, as discussed above.It should however be noted that, as the regulation of the
proteasome complex activity is a very complicated
process, it might not be possible to draw unequivocal
conclusions or deduct linear relationships.
LnCaP cells have intrinsic NEP production so
paracrine-secreted ET-1 is cleaved. Furthermore, there’s
evidence that they have decreased expression of
endothelin-converting enzyme 1 (ECE-1), with resultant
decrease in production of ET-1 [52]. It is not, therefore,
surprising that the effect of exogenous NPs on proteaso-
mal activity is comparably less intense in LnCaP cells
[45] or following rhNEP incubation in PC-3 cells. Even
at high concentrations, the NP-induced proteasomal ac-
tivity upregulation [45] does not seem to be strong
enough to result in critically low levels of IκBα, thereby
not being able to stimulate any visible nuclear NFκB
translocation, as we have demonstrated.
The underlying mechanism of NP-induced proteaso-
mal activity upregulation is not known. It could be
that NP-mediated increase in IκBα levels results in
substrate induction of the proteasome. On the other
hand, a direct NP-proteasome interaction or an NFκB-
dependent induction of expression of regulatory com-
ponents of the UPS pathway cannot be excluded and
need to be further elucidated. Also, it should be
acknowledged as a limitation of this study that our
findings were generated only with two different cell
lines (LnCaP, PC-3), although it is generally accepted
that they do represent preclinical models of AD and
AI states, respectively. It is therefore not possible to
draw a final conclusion without further studies on
other PC cell lines.
Conclusions
The data presented here suggest that NEP/NP pathway
agonists affect the activity of the NFκB/UPS pathway.
This is at least partially evidenced by NP-inducible upre-
gulation of proteasome activity which precedes IκB
degradation-dependent activation of NFκB in AI PC
cells. Recent trends in anticancer therapeutics support
the concept of combination therapies for improved effi-
cacy and spectrum of activity. Therefore, translational
research into the molecular mechanisms underlying ag-
gressive cancer phenotypes aims towards combined clin-
ical applications of antagonists/inhibitors. As such,
combined targeting of the above-mentioned pathways
may more effectively prevent survival, invasion and me-
tastasis of PC.
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